Developing Clinical Biomarkers for Mitochondrial Disease for Therapeutic Trials

27 - 28 April 2015Wellcome Genome Campus, UK

  • Summary

    Recent advances in understanding the mechanisms of mitochondrial diseases have led to the development of new treatment approaches that show real promise in animal models. The field has also come together to assemble genetically defined cohorts of patients, ready for interventional studies. However, there are a limited number of clinically-relevant biomarkers available to assess disease progression before or during treatment. The aim of this retreat was to bring together experts to help break down the biomarker ‘road-block’ and lead to well-informed treatment trials.

  • Scientific committee

    Scientific programme committee

    Patrick Chinnery

    Patrick Chinnery
    University of Newcastle, UK

    Jan Smeitink

    Jan Smeitink
    Nijmegen, The Netherlands

    Mike Murphy

    Mike Murphy
    University of Cambridge, UK